Highest-materiality recent filing
Waters Q2 revenue $1.645B beats guidance; raises full-year EPS and revenue outlook
Total revenue $1.645B; organic revenue $828M (+9% constant currency) and acquired business revenue $817M.
Waters Q1 revenue $1.267B beats guidance; raises FY2026 adjusted EPS outlook to $14.40-$14.60
Total reported revenue of $1.267B exceeded guidance by $56M; GAAP EPS ($0.87) due to acquisition charges, Adjusted EPS $2.70 (+20% YoY).
Waters subsidiary issues $3.5B in senior notes across five tranches to repay DDTL
Issuer Augusta SpinCo completed offering of $3.5B senior notes: 4.321% due 2027, 4.398% 2029, 4.656% 2031, 4.945% 2033, 5.245% 2036.
Waters provides financials for acquired BD Biosciences & Diagnostic Solutions; Q1 rev $766M
Acquisition closed Feb 9, 2026 via Reverse Morris Trust; Waters paid $4B cash distribution to BD.
Q4 sales $932M (+7% reported, +6% CC); GAAP EPS $3.77, non-GAAP EPS $4.53 (+10% YoY).
Waters completes $4B combination with BD's Biosciences & Diagnostic Solutions; forms four divisions
Consummated spin-off and merger of BD's Biosciences & Diagnostic Solutions; BD shareholders received ~0.135 Waters shares per BD share, owning 39.2% of combined company.
Waters shareholders approve BD Biosciences combination; close expected Feb 9, 2026
Approximately 99% of shares present at special meeting voted to approve share issuance for BD Biosciences deal.
Waters supplements merger proxy after two stockholder lawsuits alleging omissions
Two lawsuits filed in NY Supreme Court (Carroll, Clark) claim proxy omits material information; demand letters also received.
Waters Q3 sales $800M (+8% YoY), non-GAAP EPS $3.40 (+16%), raises FY guidance
Sales $800M, +8% as reported and constant currency, above guidance.
Waters Q2 sales $771M (+9% reported, +8% CC); GAAP EPS $2.47, non-GAAP $2.95; raises FY guidance
Sales $771M, up 9% reported and 8% constant currency vs $709M prior year.
Waters to combine with BD's Biosciences & Diagnostic Solutions in $17.5B deal
Deal valued at ~$17.5B; Waters shareholders own ~60.8%, BD shareholders ~39.2% of combined co.
Waters to acquire BD's Biosciences & Diagnostic Solutions via Reverse Morris Trust
Waters shareholders to own ~60.8% and former SpinCo shareholders ~39.2% of combined company post-merger.
Waters Q4 sales $873M beat guidance; non-GAAP EPS $4.10 up 13% YoY; FY2025 EPS guide $12.70-$13.00
Q4 sales $873M, +6% reported / +8% constant currency; exceeded high-end of guidance range.
Waters Q3 sales $740M (+4% YoY); GAAP EPS $2.71, non-GAAP $2.93; raises FY guidance
Sales $740M (+4% as reported and constant currency); GAAP EPS $2.71, non-GAAP EPS $2.93, beating guidance.
Waters Q4 2023 sales $819M (-4.5%); FY guidance organic growth -0.5% to +1.5%
Q4 GAAP EPS $3.65, non-GAAP $3.62 (at high end of guidance); YoY decline from $3.84.
Waters Q2 sales up 4% to $741M, non-GAAP EPS $2.80; lowers FY organic growth guide to 0.5-1.5%
Pharmaceutical market sales down 4% organic CC; China sales declined high teens.
Waters completes $1.36B cash acquisition of Wyatt Technology
Total purchase price of $1.36B in cash, financed via balance sheet and credit facility.
Waters Q1 sales down 1% to $685M, non-GAAP EPS $2.49; guides FY organic growth 3-5%
Q1 sales $685M (-1% reported, +3% constant currency); GAAP EPS $2.38, non-GAAP EPS $2.49, both down YoY.
Waters to acquire Wyatt Technology for $1.36B cash; Q4 revenue up 9% CC, EPS beat
Acquisition of Wyatt Technology for $1.36B cash, expected to close Q2 2023.
Waters Q3 sales $709M (+7% reported, +15% cc); raises FY22 sales guidance
GAAP EPS $2.60 flat YoY; non-GAAP EPS $2.64 vs $2.66 (FX headwind ~13%).
Waters Q2 sales $714M +10% cc, GAAP EPS $2.72, non-GAAP $2.75; raises FY sales guidance to 9.5-10.5%
Q2 sales $714M (+5% as reported, +10% constant currency); instrument sales +12% cc, recurring +8% cc.
On August 13, 2024, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Heather Knight to the Board, effective August 14, 2024, to fill the vacancy so created.
On October 18, 2023, Jonathan Pratt notified Waters Corporation (the “Company”) of his decision to resign from his position as Senior Vice President of the Waters Division, effective October 24, 2023.
On March 27, 2023, the Board of Directors (the “Board”) of Waters Corporation (the “Company”) increased the size of the Board from 9 to 10 members and appointed Richard Fearon to the Board, effective March 27, 2023, to fill the vacancy so created.
appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022
appointed Dan Brennan and Mark P. Vergnano to the Board, effective November 23, 2022
On July 28, 2022, Thomas Salice notified the Company of his decision to retire from the Board of Directors (the “Board”) as of such date.
On March 30, 2022, John Ballbach resigned from the Board of Directors (the “Board”) of Waters Corporation, effective as of such date.
On October 1, 2021, Dr. Michael Berendt notified the Board of Directors (the “Board”) of Waters Corporation (the “Company”) of his decision to retire as director of the Company, including from any committees thereof, such retirement, effective October 5, 2021.
On October 5, 2021, the Board appointed John M. Ballbach to the Board, effective October 5, 2021, to fill the vacancy left by Dr. Berendt’s retirement.
Max materiality 0.90 · Median 0.50 · Most common event earnings